Condition
Neovascularization, Pathologic
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 3 (1)
Trial Status
Completed4
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02543229Phase 1Completed
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
NCT01837160Completed
Angiogenesis and Fibrosis in Aortic Stenosis
NCT01813045Completed
Angiogenesis and Fibrosis in Myocardial Infarction
NCT02448732Early Phase 1UnknownPrimary
Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases
NCT01731262Unknown
Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis
NCT00000162Phase 3Completed
Branch Vein Occlusion Study
Showing all 6 trials